.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Army
Accenture
Colorcon
Johnson and Johnson
Teva
Mallinckrodt
Cipla
Fuji
Express Scripts
Cerilliant

Generated: December 14, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,556,864

« Back to Dashboard

Which drugs does patent 8,556,864 protect, and when does it expire?


Patent 8,556,864 protects LANTUS SOLOSTAR, APIDRA SOLOSTAR, SOLIQUA 100/33, and TOUJEO SOLOSTAR, and is included in four NDAs.

This patent has one hundred and forty-one patent family members in twenty-seven countries.

Summary for Patent: 8,556,864

Title:Drive mechanisms suitable for use in drug delivery devices
Abstract: A drive mechanism suitable for use in drug delivery devices is disclosed. The drive mechanism may be used with injector-type drug delivery devices, such as those permitting a user to set the delivery dose. The drive mechanism may include a housing, a dose dial sleeve, and a drive sleeve. A clutch is configured to permit rotation of the drive sleeve and the dose dial sleeve with respect to the housing when the dose dial sleeve and drive sleeve are coupled through the clutch. Conversely, when the dose dial sleeve and drive sleeve are in a de-coupled state, rotation of the dose dial sleeve with respect to the housing is permitted and rotation of the drive sleeve with respect to the housing is prevented. In the de-coupled state, axial movement of the drive sleeve transfers force in a longitudinal direction for actuation of a drug delivery device.
Inventor(s): Veasey; Robert Frederick (Warwickshire, GB), Perkins; Robert (Warwickshire, GB), Plumptre; David Aubrey (Worcestershire, GB)
Assignee: Sanofi-Aventis Deutschland GmbH (Frankfurt am Main, DE)
Application Number:13/075,212
Patent Claim Types:
see list of patent claims
Delivery; Device; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Sanofi Aventis UsLANTUS SOLOSTARinsulin glargine recombinantINJECTABLE;INJECTION021081-002Apr 27, 2007RXYesYes► Subscribe► Subscribe► SubscribeY
Sanofi Aventis UsAPIDRA SOLOSTARinsulin glulisine recombinantINJECTABLE;SUBCUTANEOUS021629-003Feb 24, 2009RXYesNo► Subscribe► Subscribe► SubscribeY
Sanofi-aventis UsSOLIQUA 100/33insulin glargine; lixisenatideSOLUTION;SUBCUTANEOUS208673-001Nov 21, 2016RXYesYes► Subscribe► Subscribe► SubscribeY
Sanofi Us ServicesTOUJEO SOLOSTARinsulin glargine recombinantSOLUTION;SUBCUTANEOUS206538-001Feb 25, 2015RXYesYes► Subscribe► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,556,864

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0301822.0Mar 3, 2003

Non-Orange Book Patents for Patent: 8,556,864

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,233,211Relating to a pen-type injector► Subscribe
9,028,454Drive mechanisms suitable for use in drug delivery devices► Subscribe
8,070,727Drive mechanisms suitable for use in drug delivery devices► Subscribe
9,526,843Drive mechanisms suitable for use in drug delivery devices► Subscribe
8,992,486Pen-type injector► Subscribe
8,679,069Pen-type injector► Subscribe
7,553,299Drive mechanisms suitable for use in drug delivery devices► Subscribe
9,533,105Drive mechanisms suitable for use in drug delivery devices► Subscribe
9,604,008Drive mechanisms suitable for use in drug delivery devices► Subscribe
8,512,297Pen-type injector► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,556,864

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina043458► Subscribe
Argentina043459► Subscribe
Austria394133► Subscribe
Austria405310► Subscribe
Austria406929► Subscribe
Austria422166► Subscribe
Austria474614► Subscribe
Austria497398► Subscribe
Australia2004216827► Subscribe
Australia2004216828► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

US Army
Express Scripts
Medtronic
UBS
Argus Health
Colorcon
Citi
Chubb
McKesson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot